Akkermansia muciniphila is a promising probiotic
| Autor: | Lei Cheng, Faming Zhang, Qianqian Li, Heena Buch, Ting Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
lcsh:Biotechnology
Cancer therapy Bioengineering Bioinformatics Applied Microbiology and Biotechnology Biochemistry law.invention 03 medical and health sciences Probiotic Immune system Verrucomicrobia law lcsh:TP248.13-248.65 Immune Diseases Animals Humans Immunologic Factors Medicine Intestinal Mucosa 030304 developmental biology 0303 health sciences biology 030306 microbiology business.industry Probiotics Minireviews Akkermansia biology.organism_classification Intervention studies Cancer treatment Minireview business Akkermansia muciniphila Biotechnology |
| Zdroj: | Microbial Biotechnology, Vol 12, Iss 6, Pp 1109-1125 (2019) Microbial Biotechnology |
| ISSN: | 1751-7915 |
| Popis: | Summary Akkermansia muciniphila (A. muciniphila), an intestinal symbiont colonizing in the mucosal layer, is considered to be a promising candidate as probiotics. A. muciniphila is known to have an important value in improving the host metabolic functions and immune responses. Moreover, A. muciniphila may have a value in modifying cancer treatment. However, most of the current researches focus on the correlation between A. muciniphila and diseases, and little is known about the causal relationship between them. Few intervention studies on A. muciniphila are limited to animal experiments, and limited studies have explored its safety and efficacy in humans. Therefore, a critical analysis of the current knowledge in A. muciniphila will play an important foundation for it to be defined as a new beneficial microbe. This article will review the bacteriological characteristics and safety of A. muciniphila, as well as its causal relationship with metabolic disorders, immune diseases and cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |